Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04558918 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
NCT04558918 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 97 participants.
The verdict
NCT04558918, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study was a multi-center, randomized, open-label, active comparator-controlled, parallel group study. The purpose of this Phase 3 study in PNH patients presenting with residual anemia despite treatment with anti-C5 antibody, was to determine whether iptacopan is efficacious and safe for the treatment of PNH through demonstration of superiority of iptacopan compared to anti-C5 antibody treatment.
Interventions
- DRUG Ravulizumab
- DRUG LNP023
- DRUG Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04558918
The ClinicalTrials.gov registry entry for NCT04558918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ravulizumab is the first listed.
NCT04558918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04558918 about?
NCT04558918 is a clinical study titled "Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment". This study was a multi-center, randomized, open-label, active comparator-controlled, parallel group study. The purpose of this Phase 3 study in PNH patients presenting with residual anemia despite treatment with anti-C5 antibody, was to determine whether iptacopan is efficacious and safe for the tr...
What is the current status of trial NCT04558918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2021-01-25. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT04558918?
The interventions under investigation include: Ravulizumab (DRUG), LNP023 (DRUG), Eculizumab (DRUG).
Who is sponsoring clinical trial NCT04558918?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.